Physician profile
Perry M Herman
NPI 1447200878
$2,479.60
in general payments reported to CMS, 2019-2025
34 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $174 · 2020: $160 · 2021: $244 · 2022: $1,149 · 2023: $752.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $752.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $752.25 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Nestle Healthcare Nutrition INC. | $520.07 | 2021-2023 | |
| Novo Nordisk INC | $402.13 | 2022-2023 | Rybelsus, Ozempic |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $204.29 | 2019-2023 | Xifaxan |
| Lilly USA, LLC | $164.49 | 2019-2023 | Mounjaro |
| Takeda Pharmaceuticals U.S.A., INC. | $129.20 | 2020-2022 | |
| Amgen INC. | $127.82 | 2019-2023 | Repatha, Otezla |
| Antares Pharma, INC. | $110.13 | 2022-2023 | Xyosted, Tlando, Nocdurna |
| Astrazeneca Pharmaceuticals LP | $95.93 | 2019-2022 | |
| Abbvie INC. | $88.82 | 2019-2023 | |
| Bayer Healthcare Pharmaceuticals INC. | $80.99 | 2023 | |
| Abbott Laboratories | $60.23 | 2023 | Freestyle Libre 3 |
| Jazz Pharmaceuticals INC. | $58.01 | 2021-2022 | |
| Si-Bone, INC. | $40.02 | 2021 | |
| Pfizer INC. | $32.19 | 2023 | |
| Acerus Pharmaceuticals Corporation | $28.48 | 2021-2022 |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Stimwave Technologies Incorporated | $27.73 | 2019 | |
| Paratek Pharmaceuticals, INC. | $27.08 | 2021 | |
| Bioventus LLC | $24.75 | 2020-2021 | |
| Collegium Pharmaceutical, INC. | $24.18 | 2019 | |
| Halozyme INC | $19.11 | 2023 | |
| Bausch Health US, LLC | $18.88 | 2023 | Aplenzin |
| Corcept Therapeutics | $18.56 | 2023 | Korlym |
| Azurity Pharmaceuticals, INC. | $17.36 | 2023 | Adthyza |
| Avanos Medical | $17.06 | 2022 | |
| Depuy Synthes Sales INC. | $16.72 | 2023 | Monovisc, Orthovisc |
| Lucid Diagnostics INC. | $16.50 | 2022 | |
| Shire North American Group INC | $14.97 | 2019 | |
| Biohaven Pharmaceutical Holding Company LTD. | $14.84 | 2022 | |
| Daiichi Sankyo INC. | $14.47 | 2019 | |
| Eisai INC. | $13.98 | 2020 | |
| Intra-Sana Laboratories | $13.86 | 2023 | Reltone 400 Mg, Reltone 200 Mg, Glycate |
| Exact Sciences Corporation | $13.20 | 2023 | Cologuard Collection Kit |
| Boehringer Ingelheim Pharmaceuticals, INC. | $11.87 | 2021 | |
| Alk-Abello, INC | $11.68 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Perry Herman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.